This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

JR-041

JCR Pharmaceuticals Co., Ltd.

Drug Names(s): JR-041

Description: JR-041 is a Follicle stimulating hormone therapy.

Deal Structure: JCR and ASKA
In March 2007, Asuka Pharmaceutical Co has signed an agreement with Japan Chemical Research for JR-041 for the development and manufacturing rights worldwide. Under terms of the agreement, Asuka will develop JR-041 in Japan, Europe, and the United States.

Partners: Aska Pharmaceutical Company Limited


JR-041 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug